21 Feb 2018 by admin in UncategorizedComments Centrexion Therapeutics Announces First Patient Dosed in Phase 3 Trial of CNTX-4975 for the Treatment of Moderate to Severe Knee Osteoarthritis Pain
07 Feb 2018 by admin in UncategorizedComments Syros Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
